Background Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such
as erlotinib, are standard-of-care for patients with EGFR mutation-positive non-small-cell …

Lung cancer is a leading cause of death for both men and women. The treatment of lung
cancer has been stifled with pessimism for many years. However, molecularly targeted …

Erlotinib—an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)—
has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer …

Background: Gefitinib is a first-generation epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI). It was approved by the US Food and Drug Administration (FDA) for …

The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …

Improving treatment options and patient outcomes for those with non-small cell lung cancer
(NSCLC) represents a significant worldwide challenge. Although traditional treatment …

Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …

The clinical success of EGF receptor (EGFR) inhibitors in patients with lung cancer is limited
by the inevitable development of treatment resistance. Two reports in this issue of Cancer …

BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Background It is controversial for the use of survival surrogate end points including response
rate (RR), disease control rate (DCR), time to progression, and progression-free survival …